Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Qizhen Shi MD, PhD

Qizhen Shi MD, PhD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology


Research Experience

  • hemophilia, the association between VWF and FVIII, gene therapy, immune response in hemophilia gene therapy
  • Publications

  • The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. (Shi Q, Schroeder JA, Kuether EL, Montgomery RR) J Thromb Haemost 2015 Jul;13(7):1301-9 PMID: 25955153 PMCID: PMC4496307
  • Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome. (Kanaji S, Fahs SA, Ware J, Montgomery RR, Shi Q) J Thromb Haemost 2014 Oct;12(10):1726-32 PMID: 25066812 PMCID: PMC4194147
  • Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. (Mannucci PM, Shi Q, Bonanad S, Klamroth R) Haemophilia 2014 Sep;20 Suppl 6:2-16 PMID: 24975700
  • In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. (Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q) J Thromb Haemost 2014 Aug;12(8):1283-93 PMID: 24931217 PMCID: PMC4127102
  • A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. (Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR) Blood 2014 Jun 12;123(24):3706-13 PMID: 24705491 PMCID: PMC4055921
  • Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. (Shi Q, Kuether EL, Chen Y, Schroeder JA, Fahs SA, Montgomery RR) Blood 2014 Jan 16;123(3):395-403 PMID: 24269957 PMCID: PMC3894495
  • Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. (Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA) Nat Commun 2013;4:2773 PMID: 24253479 PMCID: PMC3868233
  • Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. (Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q) Mol Ther 2014 Jan;22(1):169-77 PMID: 24042561 PMCID: PMC3978792
  • Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo. (Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR) J Thromb Haemost 2012 Nov;10(11):2328-37 PMID: 22908929 PMCID: PMC3670966
  • Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. (Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR) J Thromb Haemost 2012 Aug;10(8):1646-52 PMID: 22642380 PMCID: PMC3419786
  • Lentivirus-mediated platelet gene therapy of murine hemophilia¬†A with pre-existing anti-factor¬†VIII immunity. (Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q) J Thromb Haemost 2012 Aug;10(8):1570-80 PMID: 22632092 PMCID: PMC3419807
  • Platelet and endothelial expression of clotting factors for the treatment of hemophilia. (Montgomery RR, Shi Q) Thromb Res 2012 May;129 Suppl 2:S46-8 PMID: 22421106 PMCID: PMC3581347
  • Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice. (Shi Q, Kuether EL, Schroeder JA, Fahs SA, Montgomery RR) Haemophilia 2012 Jul;18(4):639-46 PMID: 22221819 PMCID: PMC3323668
  • Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy. (Kanaji S, Kuether EL, Fahs SA, Schroeder JA, Ware J, Montgomery RR, Shi Q) Mol Ther 2012 Mar;20(3):625-32 PMID: 22044935 PMCID: PMC3293608
  • Alternative strategies for gene therapy of hemophilia. (Montgomery RR, Shi Q) Hematology Am Soc Hematol Educ Program 2010;2010:197-202 PMID: 21239794 PMCID: PMC3383974
  • Platelets as delivery systems for disease treatments. (Shi Q, Montgomery RR) Adv Drug Deliv Rev 2010 Sep 30;62(12):1196-203 PMID: 20619307 PMCID: PMC2991519
  • Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. (Shi Q, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgomery RR) Blood 2010 Oct 21;116(16):3049-57 PMID: 20606161 PMCID: PMC2974610
  • Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. (Zhang G, Shi Q, Fahs SA, Kuether EL, Walsh CE, Montgomery RR) Blood 2010 Aug 26;116(8):1235-43 PMID: 20445020 PMCID: PMC2938234
  • Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. (Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR) Blood 2008 Oct 1;112(7):2713-21 PMID: 18495954 PMCID: PMC2556608
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID: 17269937
  • Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. (Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR) J Clin Invest 2006 Jul;116(7):1974-82 PMID: 16823491 PMCID: PMC1483176
  • Regulated release of VWF and FVIII and the biologic implications. (Haberichter SL, Shi Q, Montgomery RR) Pediatr Blood Cancer 2006 May 1;46(5):547-53 PMID: 16470522
  • Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. (Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR) J Thromb Haemost 2004 Nov;2(11):1989-97 PMID: 15550031
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID: 14675082
  • Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. (Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M) Blood 2003 Dec 1;102(12):4006-13 PMID: 12881300
  • Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. (Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR) Mol Genet Metab 2003 May;79(1):25-33 PMID: 12765843
  • Last update: 07/06/2015